FDA supplemental approval: Kadcyla (Labeling)

AI Summary

This is a supplemental FDA approval action for labeling of ado-trastuzumab emtansine (Kadcyla), issued on 26 March 2026. The record documents a regulatory decision to modify product labeling but does not contain or report clinical trial results, efficacy data, or safety comparisons. Clinicians should refer to the updated product label and the underlying clinical evidence cited therein for prescribing guidance.

Plain-language summary

This is an FDA supplemental approval action for labeling of an already-approved drug; it documents a regulatory decision, not clinical trial evidence or efficacy data.

Reported figures

Quoted from the source exactly as published.

Caveats

• This regulatory record does not contain clinical trial results, efficacy data, safety outcomes, or comparative evidence.
• The specific labeling changes made are not detailed in this record.
• No information on indications, contraindications, or updated warnings is provided in the record text.
• Clinical decision-making should be informed by the full product label and the clinical literature, not this approval notice alone.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.